1. Phylogeny  
   Tyrosine‐protein kinase Fyn (UniProt ID: P06241) is an evolutionarily ancient member of the Src family kinases (SFKs), a group of non‐receptor tyrosine kinases that play central roles in intracellular signaling. Its evolutionary history is deeply rooted in vertebrate biology, with orthologs identified in all mammalian species as well as in other metazoan lineages. Comparative sequence analyses demonstrate that Fyn shares a conserved modular domain organization with other SFK members such as Src, Yes, Lyn, Lck, Hck, Fgr, and Blk, along with rarer members like Yrk that have arisen by gene duplication events (brignatz2009alternativesplicingmodulates pages 1-2). The evolution of the Fyn gene has been further shaped by alternative splicing events that generate structurally and functionally distinct isoforms. In particular, the FynB isoform is predominantly expressed in the central nervous system, whereas the FynT isoform is largely restricted to hematopoietic cells; these differences arise from the inclusion or exclusion of regulatory exons that encode parts of the SH2–kinase linker region, thereby influencing kinase autoinhibition and substrate interactions (brignatz2009alternativesplicingmodulates pages 7-9, demuro2021gsk3βfynand pages 4-5). Thus, Fyn is placed within a highly conserved evolutionary clade alongside other Src family kinases, with its core structure and regulatory motifs preserved from early vertebrate evolution to modern organisms (elias2015fynisan pages 13-16, liu1998engineeringsrcfamily pages 7-9).
2. Reaction Catalyzed  
   Fyn catalyzes an ATP-dependent phosphorylation reaction that involves the transfer of the terminal γ-phosphate from ATP to a tyrosine residue on a specific substrate protein. The generalized chemical reaction can be expressed as:  
     ATP + [protein]-tyrosine → ADP + [protein]-phosphotyrosine + H⁺  
   In this reaction, ATP binds to the active site located within the catalytic (SH1) domain of Fyn; key residues coordinate binding of both ATP and divalent metal ions, which in turn align the γ-phosphate for nucleophilic attack by the hydroxyl group of a tyrosine residue on the substrate. This phosphorylation event introduces a negative charge at the modification site, which can alter protein conformation, subcellular localization, and intermolecular interactions; collectively, these modifications modulate downstream signaling pathways involved in processes such as cell growth, differentiation, adhesion, and motility (peng2023fynemergingbiological pages 1-3, nakamura2001activatedfynphosphorylates pages 2-3).
3. Cofactor Requirements  
   The catalytic activity of Fyn is dependent on specific cofactors, particularly divalent metal ions. Mg²⁺ is a critical cofactor for Fyn’s kinase activity; magnesium ions interact with ATP’s phosphate groups, thereby stabilizing the nucleotide in the correct orientation within the active site. This coordination not only facilitates the correct positioning of ATP but also lowers the activation energy required for the phosphoryl transfer reaction, making the catalysis efficient (liu1998engineeringsrcfamily pages 7-9).
4. Substrate Specificity  
   The substrate specificity of Fyn is determined by the interplay of its catalytic domain and its regulatory domains, including the SH2 and SH3 domains. The catalytic (SH1) domain is responsible for the chemical transfer of the phosphate group, whereas the SH2 and SH3 domains contribute to substrate recognition and docking by interacting with specific motifs on substrate proteins. The SH2 domain specifically binds phosphotyrosine-containing motifs, while the SH3 domain recognizes polyproline type II (PPII) helix-forming sequences; these interactions align substrates with the active site for efficient phosphorylation (peng2023fynemergingbiological pages 3-5, peng2023fynemergingbiological pages 5-7). Experimental mapping of phosphorylation events has revealed that Fyn preferentially targets tyrosine residues that are flanked by acidic and hydrophobic amino acids. For example, substrates involved in cell adhesion and cytoskeletal dynamics such as β-catenin (CTNNB1) and δ-catenin (CTNND1) display acidic residues upstream and hydrophobic residues immediately adjacent to the target tyrosine, thereby forming a consensus recognition environment that facilitates substrate docking and efficient catalysis (corwin2016decipheringhumancytoplasmic pages 94-97, schenone2011fynkinasein pages 1-2).
5. Structure  
   Fyn is a 59-kDa non-receptor tyrosine kinase composed of 537 amino acids, exhibiting the characteristic modular architecture of Src family kinases. Its structure is organized into several distinct domains that perform both catalytic and regulatory functions:  • The N-terminal SH4 domain contains a myristoylation signal at glycine and additional palmitoylation sites at conserved cysteine residues. These lipid modifications are crucial for the stable membrane association of Fyn, ensuring that the kinase is correctly localized to the inner leaflet of the plasma membrane where many of its substrates reside (matrone2020fyntyrosinekinase pages 12-14, liu1998engineeringsrcfamily pages 7-9).  
    • Directly following the SH4 domain is a Unique Region that exhibits significant sequence variability among SFKs. This region contributes to isoform-specific functions and regulatory interactions. Alternative splicing events within this region lead to the production of different Fyn isoforms (FynB and FynT), each with distinct cellular distributions and regulatory properties (brignatz2009alternativesplicingmodulates pages 7-9).  
    • The central SH3 domain is composed primarily of β-sheets organized into a structure that binds proline-rich motifs (PPII helices) found in various substrates and adaptor proteins. This interaction is critical for stabilizing autoinhibitory conformations in the absence of activating signals, as the SH3 domain can interact with the linker region connecting the SH2 and catalytic domains (schenone2011fynkinasein pages 1-2, peng2023fynemergingbiological pages 3-5).  
    • Following the SH3 domain is the SH2 domain, which binds to phosphotyrosine-containing motifs. This binding can occur in cis (intramolecularly) or in trans (with other proteins), serving both to recruit substrates and to stabilize the inactive conformation through binding to a phosphorylated residue in the C-terminal tail (schenone2011fynkinasein pages 1-2, peng2023fynemergingbiological pages 1-3).  
    • The C-terminal catalytic kinase domain (SH1) is organized into a bilobed structure. The smaller N-terminal lobe dominates in ATP binding, featuring a glycine-rich loop that interacts with the phosphate groups of ATP. The larger C-terminal lobe houses the catalytic machinery, including the activation loop (A-loop), a hydrophobic spine, and the critical αC-helix. The activation loop undergoes conformational shifts upon phosphorylation, which is essential for aligning the hydrophobic spine and enabling full catalytic activity. In its autoinhibited state, the phosphorylated form of the C-terminal tail (e.g., Tyr531 in FynB or Tyr528 in FynT) interacts with the SH2 domain, locking the kinase in a closed conformation that restricts substrate access (matrone2020fyntyrosinekinase pages 12-14, liu1998engineeringsrcfamily pages 7-9, schenone2011fynkinasein pages 1-2).  
   This integrated structural organization allows Fyn to function as both a sensor and an effector in complex signaling networks through precise spatial and temporal control of its catalytic activity.
6. Regulation  
   Fyn’s activity is finely tuned by multiple regulatory mechanisms that include reversible post-translational modifications and conformational dynamics mediated by its modular domains. A major regulatory mechanism involves reversible phosphorylation at specific tyrosine residues:  • In the activation loop of the catalytic domain, phosphorylation of a key tyrosine residue (Tyr420 in the FynB isoform or Tyr417 in FynT) transitions the kinase into an active conformation. This modification induces structural rearrangements in the activation loop and repositions the αC-helix, which facilitates the alignment of the hydrophobic spine necessary for full catalytic activity (nakamura2001activatedfynphosphorylates pages 2-3, peng2023fynemergingbiological pages 1-3).  
    • Conversely, phosphorylation of a conserved tyrosine residue located in the C-terminal tail (Tyr531 in FynB or Tyr528 in FynT) is essential for maintaining the autoinhibited state of Fyn. This phosphorylation event creates a binding site for the SH2 domain, which engages in an intramolecular interaction with the phosphorylated tail, thereby stabilizing an inactive conformation that prevents substrate access to the kinase active site (brignatz2009alternativesplicingmodulates pages 1-2, nakamura2001activatedfynphosphorylates pages 3-5).  
   In addition to these phosphorylation events, alternative splicing of the fyn gene modulates regulatory properties by producing isoforms with differences in the Unique Region and the SH2–kinase linker. Such variation affects the binding affinities of the intramolecular contacts between regulatory domains and the catalytic core, and therefore influences the overall threshold for kinase activation (brignatz2009alternativesplicingmodulates pages 7-9, demuro2021gsk3βfynand pages 4-5).  
   Furthermore, the SH2 and SH3 domains participate in autoinhibitory intramolecular interactions under basal conditions. The SH3 domain commonly binds to proline-rich motifs in the linker region, while the SH2 domain generates a clamp-like association with the phosphorylated C-terminal tail. Together, these interactions create a “latch-clamp” mechanism that maintains Fyn in an inactive state until appropriate activating signals, such as those provided by binding partners or phosphorylation by upstream kinases like protein kinase A (PKA), induce conformational changes that relieve autoinhibition (peng2023fynemergingbiological pages 3-5, schenone2011fynkinasein pages 1-2, nakamura2001activatedfynphosphorylates pages 3-5).  
   These layers of regulation ensure that Fyn’s kinase activity is context-dependent and responsive to cellular cues, thereby allowing precise modulation of downstream signaling events.
7. Function  
   Fyn functions as a central mediator of multiple signaling pathways that control critical cellular processes, including cell growth, survival, adhesion, migration, and differentiation. Its substrate repertoire is expansive, reflecting its roles in diverse biological contexts:  • In cell adhesion and cytoskeletal regulation, Fyn phosphorylates key components such as β-catenin (CTNNB1) and δ-catenin (CTNND1). These post-translational modifications alter the dynamics of adherens junctions, thereby modulating cell–cell adhesion and the remodeling of the cytoskeleton necessary for cell motility and tissue architecture maintenance (peng2023fynemergingbiological pages 1-3, corwin2016decipheringhumancytoplasmic pages 94-97).  
    • Fyn also regulates cytoskeletal dynamics by phosphorylating actin regulators and microtubule-associated proteins, including WAS and the microtubule-associated proteins MAP2 and MAPT. Through these interactions, Fyn contributes to the organization of the actin cytoskeleton and microtubule network, processes that are essential in neuronal development and the maintenance of synaptic structures (peng2023fynemergingbiological pages 5-7).  
    • In terms of cell survival, Fyn phosphorylates survival factors such as AGAP2/PIKE-A; this modification protects cells from apoptosis by preventing the proteolytic cleavage of pro-survival proteins. Such activity is particularly relevant in conditions where cell survival is critical, as well as in certain pathological contexts like cancer (elias2015fynisan pages 13-16, peng2023fynemergingbiological pages 1-3).  
    • Within immune cell signaling, Fyn is integral to T-cell receptor (TCR) signaling. It phosphorylates downstream substrates that regulate T-cell activation, differentiation, and proliferation. Fyn also modulates negative feedback loops within TCR signaling via substrate phosphorylation of regulatory proteins, thereby fine-tuning immune responses (corwin2016decipheringhumancytoplasmic pages 94-97, schenone2011fynkinasein pages 1-2).  
    • In the nervous system, Fyn plays a prominent role in neuronal differentiation, axon guidance, and synaptic plasticity. It is involved in reelin-mediated signaling pathways, where it phosphorylates the adapter protein DAB1 following reelin receptor engagement, thereby influencing neuronal positioning and connectivity. Fyn’s activity in these pathways is critical for proper brain development and maintenance of neural circuits (brignatz2009alternativesplicingmodulates pages 1-2, nakamura2001activatedfynphosphorylates pages 3-5).  
    • Fyn also contributes to the maintenance of specialized structures such as the glomerular slit diaphragm in the kidney. Through phosphorylation of key proteins that comprise the slit diaphragm, Fyn plays a role in regulating the integrity of the renal filtration barrier (peng2023fynemergingbiological pages 1-3).  
   Overall, Fyn’s ability to phosphorylate a diverse array of substrate proteins positions it as an essential signaling hub that integrates inputs from multiple signaling pathways and modulates downstream responses that impact cell adhesion, cytoskeletal dynamics, immune function, neural connectivity, and survival mechanisms.
8. Other Comments  
   Due to its central role in mediating intracellular signaling, dysregulation of Fyn has significant implications in human disease. Aberrant activation or overexpression of Fyn is associated with various types of cancer, where excessive kinase activity drives uncontrolled cell proliferation, enhances invasive behavior, and confers resistance to apoptosis. These oncogenic properties have been documented in studies that correlate Fyn overactivity with tumor progression in malignancies such as breast cancer, prostate cancer, and hematological cancers (elias2015fynisan pages 13-16, peng2023fynemergingbiological pages 14-14).  
   In the realm of neurodegenerative disorders, Fyn’s involvement in neural signaling and synaptic modulation links its dysregulation to conditions such as Alzheimer’s and Parkinson’s diseases; disruptions in Fyn-mediated phosphorylation events can lead to aberrant synaptic function and compromised neuronal connectivity (brignatz2009alternativesplicingmodulates pages 1-2, demuro2021gsk3βfynand pages 4-5).  
   The challenge in targeting Fyn therapeutically arises from the high degree of structural conservation within the Src family kinases, which complicates the development of selective inhibitors. Many current inhibitors that target the ATP-binding pocket of Fyn also affect related kinases, thus prompting efforts to design compounds that more specifically disrupt the protein–protein interactions mediated by the SH2 and SH3 domains or that stabilize the unique autoinhibited conformation of Fyn (schenone2011fynkinasein pages 1-2, peng2023fynemergingbiological pages 14-14).  
   In addition to small molecule inhibitors, alternative therapeutic strategies under investigation include the use of biologics or peptides that interfere with Fyn’s domain–domain interactions to achieve a more selective suppression of its kinase activity. The expression of specific Fyn isoforms, resulting from alternative splicing events, further complicates the landscape; isoform-specific targeting may provide greater therapeutic precision, particularly when distinct isoforms are associated with particular tissue types or pathological conditions.  
   Overall, Fyn’s fundamental role in diverse signaling networks not only underscores its biological importance but also highlights its potential as a target for therapeutic intervention in cancer, neurodegeneration, and immune disorders.
9. References  
   • brignatz2009alternativesplicingmodulates pages 1-2  
   • brignatz2009alternativesplicingmodulates pages 7-9  
   • corwin2016decipheringhumancytoplasmic pages 94-97  
   • demuro2021gsk3βfynand pages 4-5  
   • elias2015fynisan pages 13-16  
   • liu1998engineeringsrcfamily pages 7-9  
   • matrone2020fyntyrosinekinase pages 12-14  
   • nakamura2001activatedfynphosphorylates pages 2-3  
   • nakamura2001activatedfynphosphorylates pages 3-5  
   • peng2023fynemergingbiological pages 1-3  
   • peng2023fynemergingbiological pages 3-5  
   • peng2023fynemergingbiological pages 5-7  
   • peng2023fynemergingbiological pages 14-14  
   • schenone2011fynkinasein pages 1-2

References

1. (brignatz2009alternativesplicingmodulates pages 1-2): C. Brignatz, C. Brignatz, M. Paronetto, Sandrine Opi, Sandrine Opi, M. Cappellari, Stéphane Audebert, Stéphane Audebert, V. Feuillet, V. Feuillet, G. Bismuth, G. Bismuth, Serge Roche, Stefan T. Arold, Claudio Sette, Yves Collette, and Yves Collette. Alternative splicing modulates autoinhibition and sh3 accessibility in the src kinase fyn. Molecular and Cellular Biology, 29:6438-6448, Dec 2009. URL: https://doi.org/10.1128/mcb.00398-09, doi:10.1128/mcb.00398-09. This article has 43 citations and is from a domain leading peer-reviewed journal.
2. (corwin2016decipheringhumancytoplasmic pages 94-97): T Corwin. Deciphering human cytoplasmic protein tyrosine kinase phosphorylation specificity in yeast. Unknown journal, 2016.
3. (demuro2021gsk3βfynand pages 4-5): Stefania Demuro, Rita M. C. Di Martino, Jose A. Ortega, and Andrea Cavalli. Gsk-3β, fyn, and dyrk1a: master regulators in neurodegenerative pathways. International Journal of Molecular Sciences, 22:9098, Aug 2021. URL: https://doi.org/10.3390/ijms22169098, doi:10.3390/ijms22169098. This article has 67 citations and is from a peer-reviewed journal.
4. (elias2015fynisan pages 13-16): Daniel Elias and Henrik J. Ditzel. Fyn is an important molecule in cancer pathogenesis and drug resistance. Pharmacological Research, 100:250-254, Oct 2015. URL: https://doi.org/10.1016/j.phrs.2015.08.010, doi:10.1016/j.phrs.2015.08.010. This article has 138 citations and is from a highest quality peer-reviewed journal.
5. (liu1998engineeringsrcfamily pages 7-9): Yi Liu, Kavita Shah, Feng Yang, Laurie Witucki, and Kevan M. Shokat. Engineering src family protein kinases with unnatural nucleotide specificity. Chemistry & Biology, 5:91-101, Feb 1998. URL: https://doi.org/10.1016/s1074-5521(98)90143-0, doi:10.1016/s1074-5521(98)90143-0. This article has 255 citations.
6. (matrone2020fyntyrosinekinase pages 12-14): Carmela Matrone, Federica Petrillo, Rosarita Nasso, and Gabriella Ferretti. Fyn tyrosine kinase as harmonizing factor in neuronal functions and dysfunctions. International Journal of Molecular Sciences, 21:4444, Jun 2020. URL: https://doi.org/10.3390/ijms21124444, doi:10.3390/ijms21124444. This article has 77 citations and is from a peer-reviewed journal.
7. (nakamura2001activatedfynphosphorylates pages 2-3): Takeshi Nakamura, Hiroshi Yamashita, Tetsuya Takahashi, and Shigenobu Nakamura. Activated fyn phosphorylates α-synuclein at tyrosine residue 125. Biochemical and Biophysical Research Communications, 280:1085-1092, Feb 2001. URL: https://doi.org/10.1006/bbrc.2000.4253, doi:10.1006/bbrc.2000.4253. This article has 180 citations and is from a peer-reviewed journal.
8. (nakamura2001activatedfynphosphorylates pages 3-5): Takeshi Nakamura, Hiroshi Yamashita, Tetsuya Takahashi, and Shigenobu Nakamura. Activated fyn phosphorylates α-synuclein at tyrosine residue 125. Biochemical and Biophysical Research Communications, 280:1085-1092, Feb 2001. URL: https://doi.org/10.1006/bbrc.2000.4253, doi:10.1006/bbrc.2000.4253. This article has 180 citations and is from a peer-reviewed journal.
9. (peng2023fynemergingbiological pages 1-3): Sanfei Peng and Yang Fu. Fyn: emerging biological roles and potential therapeutic targets in cancer. Journal of Translational Medicine, Feb 2023. URL: https://doi.org/10.1186/s12967-023-03930-0, doi:10.1186/s12967-023-03930-0. This article has 46 citations and is from a peer-reviewed journal.
10. (peng2023fynemergingbiological pages 14-14): Sanfei Peng and Yang Fu. Fyn: emerging biological roles and potential therapeutic targets in cancer. Journal of Translational Medicine, Feb 2023. URL: https://doi.org/10.1186/s12967-023-03930-0, doi:10.1186/s12967-023-03930-0. This article has 46 citations and is from a peer-reviewed journal.
11. (peng2023fynemergingbiological pages 3-5): Sanfei Peng and Yang Fu. Fyn: emerging biological roles and potential therapeutic targets in cancer. Journal of Translational Medicine, Feb 2023. URL: https://doi.org/10.1186/s12967-023-03930-0, doi:10.1186/s12967-023-03930-0. This article has 46 citations and is from a peer-reviewed journal.
12. (peng2023fynemergingbiological pages 5-7): Sanfei Peng and Yang Fu. Fyn: emerging biological roles and potential therapeutic targets in cancer. Journal of Translational Medicine, Feb 2023. URL: https://doi.org/10.1186/s12967-023-03930-0, doi:10.1186/s12967-023-03930-0. This article has 46 citations and is from a peer-reviewed journal.
13. (schenone2011fynkinasein pages 1-2): S. Schenone, C. Brullo, F. Musumeci, M. Biava, F. Falchi, and M. Botta. Fyn kinase in brain diseases and cancer: the search for inhibitors. Current Medicinal Chemistry, 18:2921-2942, Jun 2011. URL: https://doi.org/10.2174/092986711796150531, doi:10.2174/092986711796150531. This article has 88 citations and is from a peer-reviewed journal.
14. (brignatz2009alternativesplicingmodulates pages 7-9): C. Brignatz, C. Brignatz, M. Paronetto, Sandrine Opi, Sandrine Opi, M. Cappellari, Stéphane Audebert, Stéphane Audebert, V. Feuillet, V. Feuillet, G. Bismuth, G. Bismuth, Serge Roche, Stefan T. Arold, Claudio Sette, Yves Collette, and Yves Collette. Alternative splicing modulates autoinhibition and sh3 accessibility in the src kinase fyn. Molecular and Cellular Biology, 29:6438-6448, Dec 2009. URL: https://doi.org/10.1128/mcb.00398-09, doi:10.1128/mcb.00398-09. This article has 43 citations and is from a domain leading peer-reviewed journal.